Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

- PMLiVE

Angelini to market Ariad’s Iclusig in Eastern Europe

Comes after leukaemia drug passes EMA safety review

- PMLiVE

Dendreon to go to auction without initial bidder

A selection for a bidder wanting to pay the minimum price has not been made

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

- PMLiVE

Pfizer’s Dr Simon Campbell recognised in UK’s New Year Honours

Recipients also include NICE’s Professor Carole Longson

- PMLiVE

Turkey: A growing pharma market with huge potential

The Turkish biopharma market offers many opportunities - if it can overcome its sustainability challenge

- PMLiVE

Celgene promotes senior EMEA figures

Marie-France Tschudin and Stefano Portolano take on new roles

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

- PMLiVE

EMA picks projects for adaptive licensing project

Begins discussions on how the model will be implemented in practice

Astellas forges $675m muscle alliance with Cytokinetics

Extendscollaboration to include neuromuscular diseases

NICE rejection of three ovarian cancer drugs stands

Agency will still not recommend Gemzar, Hycamtin and Yondelis for the disease

- PMLiVE

Media planning on a global scale

Think international when combining the most appropriate media vehicles and formats for marketing efforts

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links